NCT06206811View on ClinicalTrials.gov

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

February 12, 2024

Primary Completion Date

November 25, 2024

Study Completion Date

November 25, 2024

Conditions
Inflammatory Bowel DiseasesBlau SyndromeCrohn DiseaseUlcerative ColitisSpondyloarthritis
Interventions
DRUG

OD-07656

innate immune modulator

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

Sponsors
All Listed Sponsors
lead

Odyssey Therapeutics

INDUSTRY

NCT06206811 - Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter